Molika Ashford

Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.

Researchers described the process they took to adapt their methodology for improved BRCA variant classification through ClinGen in a new study this week.

Neurologists treating patients who present with a small stroke or transient ischemic attack are now able to get PGx results to inform their prescription of Plavix within 24 hours.

Investigators from Atrium Health recently published a study comparing pretreatment and posttreatment testing, showing a strong benefit in a real-world clinical cohort.

The collaboration aims to develop an improved stool-based CRC screening option, leveraging biomarkers discovered at the Netherlands Cancer Institute.

Investigators last month published early results, which they believe have set a solid foundation for the independent value of their novel signature.

Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.

As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.

At ASCO's annual meeting, audience questions on hypothetical cases revealed that oncologists are already having to make decisions about MCED use despite lingering unanswered questions.

Although leading labs have coalesced around the value of protocols for making sure updated variant calls get to patients, strategies still vary and practical challenges remain.